Carson, Joanne M; Barbieri, Sebastiano; Cunningham, Evan; Mao, Eric; van der Valk, Marc; Rockstroh, Jürgen K; Hellard, Margaret; Kim, Arthur; Bhagani, Sanjay; Feld, Jordan J; Gane, Ed; Thurnheer, Maria C; Bruneau, Julie; Tu, Elise; Dore, Gregory J; Matthews, Gail V; Martinello, Marianne (2023). Sexual and drug use risk behaviour trajectories among people treated for recent HCV infection: the REACT study. Journal of the International AIDS Society, 26(9), e26168. BioMed Central 10.1002/jia2.26168
|
Text
Journal_of_the_International_AIDS_Society_-_2023_-_Carson.pdf - Published Version Available under License Creative Commons: Attribution (CC-BY). Download (900kB) | Preview |
INTRODUCTION
Exploration of sexual and drug use behaviours following treatment for recent hepatitis C virus (HCV) is limited. This analysis modelled behavioural trajectories following treatment for recent HCV and assessed reinfection.
METHODS
Participants treated for recent HCV in an international trial (enrolled 2017-2019) were followed at 3-monthly intervals for up to 2 years to assess longitudinal behaviours. Population-averaged changes were assessed using generalized estimating equations. Distinct behavioural trajectories were identified using group-based trajectory modelling. HCV reinfection incidence was calculated using person-years (PY) of observation.
RESULTS
During the follow-up of 212 participants (84% gay and bisexual men [GBM]; 69% HIV; 26% current injecting drug use [IDU]), behavioural trajectories for IDU and stimulant use (past month) did not change. However, population-averaged decreases in the likelihood of daily IDU (adjusted odds ratio [AOR] 0.83; 95% CI 0.72, 0.95) and opioid use (AOR 0.84; 95% CI 0.75, 0.93) were observed. Among GBM, behavioural trajectories for chemsex did not change. Population-averaged decreases in condomless anal intercourse with casual male partners (CAI-CMP) (AOR 0.95; 95% CI 0.90, 0.99) and group-sex (AOR 0.86; 95% CI 0.80, 0.93) were observed, but masked distinct trajectories. While a proportion had a decreased probability of CAI-CMP (23%) and group-sex (59%) post-treatment, a substantial proportion retained a high probability of these behaviours. High HCV reinfection incidence was observed for the sustained high probability IDU (33.0/100 PY; 95% CI 17.7, 61.3) and chemsex (23.3/100 PY; 95% CI 14.5, 37.5) trajectories.
CONCLUSIONS
Limited sexual and drug use behavioural change was observed following treatment for recent HCV, supporting access to surveillance and (re)treatment.
Item Type: |
Journal Article (Original Article) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Infectiology |
UniBE Contributor: |
Thurnheer Zürcher, Maria Christine |
Subjects: |
600 Technology > 610 Medicine & health |
ISSN: |
1758-2652 |
Publisher: |
BioMed Central |
Language: |
English |
Submitter: |
Pubmed Import |
Date Deposited: |
11 Sep 2023 15:28 |
Last Modified: |
29 Oct 2023 02:22 |
Publisher DOI: |
10.1002/jia2.26168 |
PubMed ID: |
37675828 |
Uncontrolled Keywords: |
GBM HCV HIV PWID STI reinfection |
BORIS DOI: |
10.48350/186147 |
URI: |
https://boris.unibe.ch/id/eprint/186147 |
Actions (login required)
 |
Edit item |